

PRELIMINARY PROGRAM OF MAIN CONGRESS AS OF JULY 16, 2020

Dates & timing details of sessions are subject to change

CW - CLINICAL WORKSHOP

SUNDAY, JAN. 17

Revisiting high-grade intraepithelial neoplasia - Molecular biology, risk management and prevention

PART 1 - CERVIX

CW 01 A **A global picture of CIN3-ADC in situ** **8:15 - 9:45**
 Chair: S. Franceschi (Italy)

- Epidemiology
- Natural history and carcinogenesis
- HPV related prevalence, score of risk and risk calculator application
- Discussion

TBD
J. Doorbar (UK)
N. Wentzensen (USA)

CW 01 B **HPV primary screening of CIN3-ADC in situ**
New insights and long-term performance **10:15 - 11:45**
 Chair: C. Meijer (Netherlands)

- HPV based screening strategies and triage options
- Role of genotyping
- Epigenetics & Methylation
- Biomarkers for diagnosis and grading
- Performance of HPV self-sampling
- Screening of vaccinated women
- Discussion

M. Arbyn (Belgium)
J. Bonde (Denmark)
D. Heideman (Netherlands)
D. Jenkins (UK)
H. Berkhof (Netherlands)
J. Dillner (Sweden)

CW 01 C **HPV vaccines: protection against CIN3-ADC in situ** **13:15 - 14:45**
 Chair: S. Garland (Australia)

- Focus on randomized clinical trials
- Long-term impact on public health
- Defining populations at risk and individual benefits of HPV vaccines
- Residual risks of CIN-ADC in situ in HPV screening and vaccinated women
- Discussion

E. Joura (Austria)
J. Brotherton (Australia)
S. Garland (Australia)
M. Brisson (Canada)

CW 01 D **Management and follow-up of women with CIN3-ADC in situ** **15:15 - 16:45**
 Chair: J. Bornstein (Israel), J. Paavonen (Finland)

- New risk management
- The colposcopic features and assessment of CIN3
- Current treatment options
- Follow-up and management issues
- Discussion

TBD
J. Bornstein (Israel)
G. Donders (Belgium)
M. Kyrgiou (UK)

PART 2

| | | |
|--------------|---|--|
| CW 02 | <p>New insights in high-grade intraepithelial neoplasia of anus, vulva and oropharynx</p> <p>Chair: J. Palefsky (USA)</p> <hr/> <ul style="list-style-type: none"> • AIN3 • VuIN3 • PIN3 • Does oropharyngeal precancer exist? • Discussion | <p>16:45 - 18:15</p> <hr/> <p>J. Palefsky (USA) J. Paavonen (Finland) K. D'Hauwers (Netherlands) TBD</p> |
|--------------|---|--|

MSS - MAIN SCIENTIFIC SESSIONS

| | | |
|---------------|--|-----------------------------|
| MSS 01 | <p>Novel strategies in risk-based cervical cancer screening</p> <p>Chair: J. Cuzick (UK), H. Berkhof (Netherlands)</p> | <p>8:00 - 9:30</p> |
| MSS 02 | <p>Immune responses induced by different HPV vaccines and doses</p> <p>Chair: M. Lehtinen (Finland), M. Pawlita (Germany)</p> | <p>9:30 - 11:00</p> |
| MSS 03 | <p>Methylation markers</p> <p>Chair: R. Steenbergen (Netherlands)</p> <hr/> <p>Altered DNA methylation is one of the key epigenetic events that contributes to the development of cancer. Methylation of CpG rich regions within promoter regions can lead to gene silencing. HPV-driven carcinogenesis is associated with increased DNA methylation of both host cell tumor suppressor genes as well as viral genes. Change in DNA methylation patterns are already detectable at the stage of precancerous lesions and can be measured in exfoliated cells using sensitive molecular methods. Accordingly, DNA methylation analysis has been evolved as one of the most promising tools for the early detection of cancer and large clinical studies have demonstrated their applicability as triage markers in HPV-based cervical screening. This session will discuss the use of methylation markers for detection of HPV-induced cancers, including both anogenital and oropharyngeal cancers.</p> | <p>14:00 - 15:30</p> |
| MSS 04 | <p>Self-sampling</p> <p>Chair: J. Brotherton (Australia), D. Heideman (Netherlands)</p> <hr/> <p>Self-collection of (cervico-) vaginal and urine samples is getting increased attention, particularly to increase screening participation. HPV self-sampling is nowadays offered routinely in the national cervical cancer screening program in certain countries, and other countries have started trials to evaluate the approach as an alternative for clinician-based screening.</p> | <p>16:00 - 17:30</p> |

MSS 05 **Anal cancer screening** **17:30 - 19:00**
Chair: A. Nyitray (USA)

While anal cancer screening overall remains severely understudied, research to date has often focused on incidence, acceptability and screening modalities among MSM in western countries. This session will discuss differing anal cancer incidence in western and non-western regions, anal cancer screening acceptability among non-MSM populations and non-white communities, and finally, recent advancements in biomarkers to aid in risk stratification.

MSS - MAIN SCIENTIFIC SESSIONS

TUESDAY, JAN. 19

MSS 06 **HPV+ women at screening - International Guidelines** **8:00 - 9:30**
Chair: M. Arbyn (Belgium), N. Wentzensen (USA)

MSS 07 **Vaccination of treated recipients** **10:00 - 11:30**
Chair: E. Joura (Austria), D. Mesher (UK)

MSS 08 **Vaccine safety & vaccine impact** **14:15 - 15:45**
Chair: P. Bonanni (Italy), J. Dillner (Sweden)

MSS 09 **Validation of HPV testing in various situations** **16:15 - 17:45**
Chair: M. Poljak (Slovenia)

MSS 10 **Screening of vaccinated cohorts** **17:45 - 19:15**
Chair: M. Elfström (Sweden), D. Mesher (UK)

SS - SCIENTIFIC SESSIONS

SUNDAY, JAN. 17

SS **Validation of HPV assays on vaginal self-samples and urine** **13:15 - 14:45**
Chair: M. Arbyn (Belgium)

SS **Optimising HPV vaccine supply and demand for global public health impact in the post-COVID-19 era** **15:15 - 16:45**
Chair: M. Brisson (Canada), M. Jit (UK)

| | | |
|----|--|---------------|
| SS | Molecular triage approaches for HPV+ women Clinical vs. self-collected samples Chair: C. Charpentier (France), D. Jenkins (UK) | 16:45 - 18:15 |
|----|--|---------------|

SS - SCIENTIFIC SESSIONS

MONDAY, JAN. 18

| | | |
|----|---|-------------|
| SS | Epidemiology of HPV related cancer in high-risk groups Chair: M. Goodman (USA), M. Shiels (USA) | 8:00 - 9:30 |
|----|---|-------------|

| | | |
|----|--|--------------|
| SS | Quality assurance & indicators, evaluation and impact of HPV - based primary screening Chair: P. Giorgi Rossi (Italy), S. Van Dijk (Netherlands) | 9:30 - 11:00 |
|----|--|--------------|

| | | |
|----|--|---------------|
| SS | One dose vaccination Chair: A. Kreimer (USA) | 14:00 - 15:30 |
|----|--|---------------|

SS - SCIENTIFIC SESSIONS

TUESDAY, JAN. 19

| | | |
|----|--|-------------|
| SS | Genomics, biomarkers and microbiome using metabolomics and proteomics Chair: A. Moscicki (USA) | 8:00 - 9:30 |
|----|--|-------------|

Evidence strongly supports the role of the microbiome in influencing the progression of HPV to cervical precancers and cancers. However, some believe it's not just "bad" microbiome, rather an interplay between genetic predisposition and response to the altered microbiome. The study of the microbiome and host and bacterial metabolites can give important insight into pathogenesis. In addition, microbiome or metabolome signatures preceding HPV clearance or progression to HSIL may be useful as biomarkers to identify women in need of more intense observation or treatment. Metabolomics has been successfully used for biomarker discovery and technologies are being developed for point-of-care testing using non-invasive fluids (e.g., urine, feces) in resource-poor settings. This session will review the interplay of genetics, microbiomes and metabolomics.

| | | |
|----|--|---------------|
| SS | New molecular biomarkers in HPV cancer prognosis (interest for patients ultrastadification, selection of treatment, therapeutic de-escalation) and cancer monitoring Chair: L. Mirabello (USA), H. Peré (France) | 10:00 - 11:30 |
|----|--|---------------|

SS Immunology 1 **14:15 - 15:45**

Chair: S. Van der Burg (Netherlands)

- Resistance mechanisms to immunotherapy in mice
- Resistance mechanisms to immunotherapy in patients

SS Immunology 2 **16:15 - 17:45**

Chair: S. Van der Burg (Netherlands)

- Combination therapies to battle HPV-induced malignancies
- Dissecting the tumor microenvironment

CS - CLINICAL SESSIONS

MONDAY, JAN. 18

CS 01 Challenges in colposcopy practice **8:00 - 9:30**

Chair: A. Schneider (Germany), E. Siegler (Israel)

CS 02 Oncological safety & reproductive morbidity in women with CIN and local treatment **9:30 - 11:00**

Chair: M. Kyrgiou (UK), E. Paraskevaidis (Greece)

CS 03 Risk based management consensus guidelines **14:00- 16:00**

Chair: N. Wentzensen (USA)

CS - CLINICAL SESSIONS

TUESDAY, JAN. 19

CS 04 Artificial intelligence: contribution of artificial intelligence and big data in HPV driven cancer **10:00 - 11:30**

Chair: H. Peré (France), N. Wentzensen (USA)

CS 05 Pro / Con **14:15 - 15:45**

Chair: E. Franco (Canada)

CS 06 Pro / Con **16:15 - 17:45**

Chair: A. Kaufmann (Germany), M. Kyrgiou (UK)

CS 06 Surveillance of HPV related diseases **17:45 - 19:15**

Chair: M. Drolet (Canada)

The **EUROGIN HPV and Head & Neck Cancer Forum** highlights areas of active investigation in the field of HPV and head and neck cancers. This year's forum will offer an extended review of screening for early cancer detection that will occupy two sessions, molecular characterization and potential biomarkers for prognosis and monitoring of HPV related oropharyngeal cancer patients, new insights on emerging treatment strategies and the role of HPV in benign disease such as recurrent respiratory papillomatosis.

HN 01 **Management** **8:00 - 9:30**
 Chair: A. Psyrri (Greece)

- Diagnosis: Work-up of unknown primary
- Updates in deintensification
- Surgical deintensification of HPV-OPC
- Role of biomarkers in HPV-OPC treatment
- High-risk & recurrent disease
- Discussion

HN 02 **Epidemiology & prevention** **9:30 - 11:00**
 Chair: P. Bossi (Italy)

- HPV in non-oropharynx SCCa
- HPV vaccination and HPV-OPC prevention
- Updates in epidemiologic trends - oral HPV infection & HPV-OPC
- Biomarkers for HPV-OPC
- Familial occurrence of OPSCC and other HPV-associated cancers
- Discussion

HN 03 **Screening** **14:00 - 15:30**
 Chair: T. Waterboer (Germany)

- Screening for HPV-OPC: Are we there yet?
- Risk-stratified screening of OPSCC - proof of concept trial
- HIV Endeavor (HPV16 AB Detection as an Early Marker of OPSCC among men living with HIV)
- Cost-effectiveness of OPSCC elimination
- Screening trial updates
- Discussion

HN 04 **Survivorship & Surveillance** **16:00 - 17:30**
 Chair: P. Klussmann (Germany)

- HPV-OPC surveillance: standard of care & emerging biomarkers
- Patient concerns, priorities & decision-making
- Swallowing evaluation, interventions and outcomes
- Impact of deintensification on HRQOL outcomes
- The psychology of surviving a sex / STI-linked cancer like HPV-associated cancer
- Discussion

HN 06 Carcinogenesis & molecular characterization 8:00 - 9:30
Chair: Klozar (Czech Republic)

- Impact of smoking vs. HPV on carcinogenesis
- Single cell sequencing
- HPV viral integration
- Molecular modifiers of prognosis in HPV-OPC
- Liquid biopsy for HPV-OPC
- Discussion

HN 07 Immunologic considerations 10:00 - 11:30
Chair: Sikora (USA)

- Immunologic landscape in HPV+ vs HPV- HNSCC
- Immune microenvironment in HPV-OPC
- HPV-specific T cell response
- Role of immunotherapy in HPV-OPC
- Enhancing immune response to HPV-OPC: tumor vaccines, CAR-T therapy
- Discussion

HN 08 RRP 14:15 - 15:45
Chair: S. Best (USA)

- Immune therapy for RRP
- Vaccination and RRP
- TBD
- TBD
- Discussion

VULVAR AND ANAL DISEASES

Vulvovaginal diseases course

WS

Coordinators: J. Bornstein (Israel), G. Donders (Belgium),
J. Paavonen (Finland)

CERVICAL CANCER SCREENING QUALITY ASSURANCE

Cervical cancer screening quality assurance

WS

Chair: S. Van Dijk (Netherlands)

8:15 - 11:45

COLPOSCOPY COURSE Sepearate registration required

WEDNESDAY, JAN. 20

Colposcopy course

Coordination: J. Bornstein (Israel)

8:00 - 12:30

ORGANISATIONSKOMMITTEE

- Peter Hillemanns, DGGG, DKG, Studiengruppe Kolposkopie
- Volkmar Küppers, AG-CPC
- Magnus von Knebel Doeberitz
- Thomas Iftner
- Elmar Joura, Wien
- Clemens Tempfer, AGO Uterus

LW 01

HPV-Impfung

Vorsitz: E. Joura (Austria), A. Kaufmann (Germany)

13:00 - 14:15

- Aktueller Stand der HPV-Impfung
- Ist eine HPV-Impfdosis ausreichend
- HPV-Impfung nach Konisation
- HPV-Impfung in anderen Konstellationen (HIV, HNO, MSM)
- Impfprävention der Zukunft
- Discussion

E. Joura (Austria)
A. Kaufmann (Germany)
P. Hillemanns (Germany)
C. Dannecker (Germany)
M. Knebel Doeberitz (Germany)

LW 02

Gesundheitspolitik und Prävention

Vorsitz: M. Baumann (Germany), P. Hillemanns (Germany)

14:15 - 15:45

- Nationale Dekade gegen Krebs
- Covid-19-Pandemie: Lehren für die Prävention
- Welchen Effekt können wir durch das neue Zervixkarzinom-Screening in der Modellierung erwarten
- Reicht es, die Risikogruppen beim Zervixkarzinom zu screenen
- Über den Tellerrand: Neues vom Prostatakrebscreening
- Discussion

M. Baumann (Germany)
H. Streeck (Germany)
TBD
P. Hillemanns (Germany)
P. Albers (Germany)

LW 03

Zervixkarzinomscreening 2020 in Deutschland

Vorsitz: C. Dannecker (Germany), M. Hampl

16:15 - 17:45

- Nationales Screeningprogramm in Deutschland
- Probleme bei der Einführung des Screenings 2020
- Wie können wir den Abklärungsalgorithmus verbessern
- Kann das Einladungsmodell die Teilnehmerzahl zu erhöhen
- Erfahrungen vom Wolfsburger Co-Testing
- Discussion

J. Gallwas (Germany)
V. Küppers (Germany)
G. Böhmer (Germany)
M. Jentschke (Germany)
TBD

LW 04 **Plattform für junge Forscher** **8:00 - 9:30**
Vorsitz: M. Knebel Doeberitz (Germany), U. Wieland

LW 05 **Zervixkarzinomscreening – internationale Entwicklungen
(Cervical cancer screening – international developments)** **9:30 - 11:00**
Vorsitz: T. Iftner (Germany), N. Wentzensen (USA)

- Aktueller Stand des Screenings in den USA
- Screening in den Niederlanden
- Screening in Großbritannien
- Screening in Skandinavien
- Discussion

N. Wentzensen (USA)
C. Meijers (Germany)
TBD
TBD

LW 06 **Differenzialdiagnostik bei auffälligem Screeningbefund** **11:00 - 12:30**
Vorsitz: V. Küppers (Germany), C. Tempfer

- Methylierung
- Abklärungszytologie
- Abklärungskolposkopie
- Innovative Methoden mit Dual Stain, NGS und anderes
- Discussion

D. Dürst (Germany)
V. Küppers (Germany)
P. Soergel (Germany)
T. Iftner (Germany)